Join the IDMO Revolution
Clinical & Commercial cGMP Manufacturing
-
TRANSLATE YOUR PROCESS INTO THE IDMO ECOSYSTEM Transfer and automate your existing CAR-T process into the Cellares IDMO ecosystem in as few as 12 months
-
LEVERAGE CELLARES' STANDARD CAR-T PROCESS
Manufacture cGMP product using our pre-optimized, fully-automated, turnkey CAR-T process including analytics, in as few as 8 months
TRANSLATE YOUR PROCESS INTO THE IDMO ECOSYSTEM 
LEVERAGE CELLARES' STANDARD CAR-T PROCESS -
PROCESS & ANALYTICAL DEVELOPMENT
Develop, optimize, and automate your cell therapy process utilizing Cellares' manufacturing and quality control technologies
-
GLOBALIZATION PACKAGE
Using the Cellares global network of IDMO Smart Factories, rapidly expand into new markets via functionally instantaneous tech transfers
-
REGULATORY SUPPORT
Access our regulatory experts to support the generation and submission of CMC data packages
PROCESS & ANALYTICAL DEVELOPMENT 
GLOBALIZATION PACKAGE 
REGULATORY SUPPORT Working with the Cellares IDMO
Tech Translation & Feasibility
- Transfer your process and analytical assay knowledge
- Generate and execute the unit operation and analytical plan
- Execute automated manufacturing run & generate draft batch record
cGMP Bridging
- Technology transfer to cGMP laboratory & method qualification
- Engineering/comparability runs, QC test & release, and stability study initiation
- Finalize manufacturing and QC SOPs, CPPs, and CQAs
- Process characterization/validation & regulatory support
Clinical & Commercial cGMP Manufacturing
- Generate manufacturing plan and production forecast
- Produce cGMP cell therapy batches
- Final drug product QC and release
Translate and Automate Your Process or Leverage the Cellares Standard CAR-T Process
-
Advantages of Translating Your Process Into the IDMO Ecosystem
- Get to IND and BLA up to 33% faster* and accelerate global expansion
- Single technology platform that scales seamlessly as your asset progresses through development
- Up to a 50% reduction in batch price*
*Compared to conventional CDMOs -
Advantages of Using the Cellares Standard CAR-T Process
- Get to IND and BLA up to 50% faster* and accelerate global expansion
- Includes pre-qualified analytics
- Up to a 50% reduction in batch price*
- Frees you to focus resources on the biology & clinical success of your asset rather than process development & manufacturing
*Compared to conventional CDMOs
Rapidly Expand Your Cell Therapy to New Markets Leveraging the Global Network of Cellares IDMO Smart Factories
- Speed Functionally instantaneous tech transfer to additional manufacturing sites in the US, Europe and Japan
- Scalability Accelerate your ability to meet the total global patient demand
- Cost savings De-risk regional expansion by leveraging Cellares' global regulatory expertise
Flexible IDMO Service Models
Cellares is Working with 5 out of 8 of the World's Largest Pharmaceutical Companies In Cell Therapy
-
Bristol Myers Squibb
- Bristol Myers Squibb and Cellares have signed a global capacity reservation and supply agreement for the manufacture of cell therapies in a transaction valued up to $380M
- Cellares is providing proof-of-concept manufacturing for two Bristol Myers Squibb CAR-T cell therapies
-
Cabaletta Bio
- Cellares and Cabaletta Bio have partnered to validate Cellares’ Cell Shuttle platform for the manufacture of Cabaletta's CABA-201 cell therapy
- CABA-201, Cabaletta Bio’s fully human CD19-CAR T product candidate, is being evaluated in parallel phase 1/2 trials across multiple autoimmune diseases
-
Lyell
- Cellares and Lyell have partnered for proof-of-concept automated manufacture of a key Lyell CAR T-cell therapy using Cellares’ Cell Shuttle
- This collaboration will evaluate potential utilization of the Cell Shuttle for future Lyell CAR T-cell clinical trials and commercialization
